Many conventional treatments for uncomplicated malaria are failing because malaria parasites develop resistance to them. This can be reduced by treating people with combination drugs such as c-proguanil. The review found 10 trials, most of low methodological quality and most funded by a single pharmaceutical company. In addition, trials were small and had few participants thus evidence suggesting atovaquone-proguanil as more effective than a number of single drug treatments at eliminating the Plasmodium falciparum malaria parasite from the blood was limited. There were few good quality data comparing atovaquone-proguanil with other new combination therapies. There were not enough data to assess adverse events, but all trials recorded some adverse events.
Osei-Akoto, A.; Orton, L.C.; Owusu-Ofori, S. Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database of Systematic Reviews (2005) (Issue 4) Art. No.: CD004529. [DOI: 10.1002/14651858.CD004529.pub2]
Atovaquone-proguanil for treating uncomplicated malaria.